ClinVar Miner

Submissions for variant NM_025114.4(CEP290):c.4102G>A (p.Asp1368Asn)

gnomAD frequency: 0.00138  dbSNP: rs184143186
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000177662 SCV000229564 uncertain significance not provided 2017-07-25 criteria provided, single submitter clinical testing
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics RCV000177662 SCV000280622 uncertain significance not provided 2015-06-12 criteria provided, single submitter clinical testing Converted during submission to Uncertain significance.
GeneDx RCV000177662 SCV000518769 likely benign not provided 2021-01-07 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV001080328 SCV000634655 likely benign Familial aplasia of the vermis; Meckel-Gruber syndrome; Nephronophthisis 2024-01-31 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000177662 SCV004700164 likely benign not provided 2023-12-01 criteria provided, single submitter clinical testing CEP290: BS1
Natera, Inc. RCV001273073 SCV001455660 likely benign Leber congenital amaurosis 2020-04-17 no assertion criteria provided clinical testing
Genetic Services Laboratory, University of Chicago RCV003150971 SCV003839351 uncertain significance not specified 2022-05-10 no assertion criteria provided clinical testing DNA sequence analysis of the CEP290 gene demonstrated a sequence change, c.4102G>A, in exon 32 that results in an amino acid change, p.Asp1368Asn. This sequence change has been described in the gnomAD database with a frequency of 0.54% in the African/African American subpopulation (dbSNP rs184143186). The p.Asp1368Asn change affects a poorly conserved amino acid residue located in a domain of the CEP290 protein that is not known to be functional. The p.Asp1368Asn substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). This sequence change does not appear to have been previously described in individuals with CEP290-related disorders. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Asp1368Asn change remains unknown at this time.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.